-
Calls Purchased on NPS Pharmaceuticals
Thursday, August 11, 2011 - 12:24pm | 113Shares of NPS Pharmaceuticals (NASDAQ: NPSP) are higher on the session by 2.73%, currently trading at $7.16. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are buying calls on the name today. A short...
-
GenVec Renews Stockholder Rights Plan
Thursday, August 11, 2011 - 10:53am | 265GenVec, Inc. (Nasdaq: GNVC) today announced that its Board of Directors has approved the replacement of its Stockholder Rights Plan through the adoption of a new Rights Agreement. The new Stockholder Rights Plan is to become effective on September 7, 2011, which is the date that GenVec's existing...
-
Options Brief: Affymax
Thursday, August 11, 2011 - 10:06am | 68Shares of Affymax (NASDAQ: AFFY) are lower on the session by 1.24%, trading at $3.99. Overall call volume is now running at 9.89x the daily average, with 1% of all calls traded being purchases on the offer. 3,115 contracts have traded on the session so far. Affymax, Inc. is a biopharmaceutical...
-
Brean Murray Carret & Co Revises EPS Estimates Of Gilead
Thursday, August 11, 2011 - 8:53am | 48According to Brean, Gilead Sciences (NASDAQ: GILD), EPS estimates have changed. Brean reported a change in EPS estimates from $3.91 to $3.65 for FY11 and from $4.40 to $4.22 for FY12. Rating is set to Buy with a PT of $52. Gilead closed yesterday at $35.34.
-
Agenus Prices Offering of 13.72M Shares at $0.51
Thursday, August 11, 2011 - 8:33am | 98Agenus Inc. (Nasdaq: AGEN) today announced the pricing of an at market underwritten offering of 13,725,491 primary shares of its common stock at a price of $0.51 per share with a group of investors including the Company's Chairman and CEO, Dr. Garo Armen. Agenus' common stock closed at $0.51 on...
-
J.P. Morgan Reports On FDA Approval For GILD
Thursday, August 11, 2011 - 8:32am | 136J.P. Morgan is maintaining its Overweight rating on Gilead Sciences (NASDAQ: GILD) following the company's FDA approval on its latest product, Complera. Says J.P. Morgan, in its report, “This afternoon, Gilead and partner Johnson and Johnson (covered by JPM analyst Mike Weinstein) announced FDA...
-
Citi Reiterates Buy and PT of $72 on Regeneron Pharmaceuticals
Thursday, August 11, 2011 - 8:11am | 47Citi reiterated its Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN). At the same time, the rating agency left its price target on the company's stock unchanged at $72. On Wednesday, REGN lost 2.36% of its value to finish the day at $47.10.
-
Sinovac Receives GMP Certificate in Mexico for Seasonal Flu Vaccine and Hepatitis A Vaccine
Thursday, August 11, 2011 - 8:10am | 146Sinovac Biotech Ltd. (Nasdaq: SVA) announced today that it has obtained the GMP certificate for its seasonal flu vaccine and hepatitis A vaccine from the Mexican regulatory authority, the Federal Commission for the Protection Against Sanitary Risk of Mexico Ministry of Health. Sinovac is the first...
-
Affymax Announces Assignment of March 27, 2012 PDUFA Date for Peginesatide New Drug Application
Thursday, August 11, 2011 - 8:04am | 92Affymax, Inc. (Nasdaq: AFFY) today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act action date of March 27, 2012 for the review of the investigational agent peginesatide (formerly known as Hematide™) New Drug Application. The company had announced...
-
UPDATE: Rodman & Renshaw Reiterates Market Outperform on Adventrx Pharmaceuticals, Slashes PT to $9
Thursday, August 11, 2011 - 7:43am | 66Rodman & Renshaw reiterated its Market Outperform rating on Adventrx Pharmaceuticals (NYSE: ANX). At the same time, the rating agency reduced its price target on the company's stock from $16 to $9. On Wednesday, ANX had a disastrous session, losing 58.28% of its value to end the day at $1.06....
-
Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
Wednesday, August 10, 2011 - 6:26pm | 184Lexicon Pharmaceuticals (NASDAQ: LXRX) announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome were published earlier this week in the August 2011 edition of the journal Gastroenterology. The issue also included an expert...
-
Gilead Sciences Resolves FDA Warning Letter Related to San Dimas Manufacturing Facility
Wednesday, August 10, 2011 - 5:01pm | 112Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has resolved all outstanding issues raised in a Warning Letter issued by the U.S. Food and Drug Administration (FDA) in September 2010 related to its San Dimas, California manufacturing facility. The FDA notified Gilead today that the...
-
Bydureon FDA Action Date Set For January 28, 2012
Wednesday, August 10, 2011 - 4:18pm | 228Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the companies' BYDUREON™ (exenatide extended-release for injectable suspension) resubmission. The FDA...
-
FDA Approves Gilead Sciences' Complera for HIV-1 Infection in Treatment-Naïve Adults
Wednesday, August 10, 2011 - 4:06pm | 97Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults. Complera combines three antiretroviral medications in one daily tablet – Gilead's...
-
Biotech/Pharma Stocks Trading News Alert: Aethlon Medical, OXiGENE, Adventrix, Chelsea Therapeutics, Exelixis
Wednesday, August 10, 2011 - 12:39pm | 1510Point Roberts, WA - August 10, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for biotech and pharma stocks trading August 9th. Yesterday's trading session saw gains for investors in a very volatile...